Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) EBIT: 2019-2025

Historic EBIT for Nurix Therapeutics (NRIX) over the last 6 years, with Aug 2025 value amounting to -$91.4 million.

  • Nurix Therapeutics' EBIT fell 67.34% to -$91.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$267.2 million, marking a year-over-year decrease of 37.96%. This contributed to the annual value of -$213.0 million for FY2024, which is 37.38% down from last year.
  • Nurix Therapeutics' EBIT amounted to -$91.4 million in Q3 2025, which was down 89.12% from -$48.3 million recorded in Q2 2025.
  • In the past 5 years, Nurix Therapeutics' EBIT registered a high of -$24.5 million during Q1 2021, and its lowest value of -$91.4 million during Q3 2025.
  • Its 3-year average for EBIT is -$51.9 million, with a median of -$48.3 million in 2025.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 99.65% in 2021, then soared by 41.45% in 2023.
  • Over the past 5 years, Nurix Therapeutics' EBIT (Quarterly) stood at -$38.0 million in 2021, then fell by 28.29% to -$48.7 million in 2022, then rose by 6.89% to -$45.3 million in 2023, then plummeted by 42.62% to -$64.7 million in 2024, then tumbled by 67.34% to -$91.4 million in 2025.
  • Its EBIT stands at -$91.4 million for Q3 2025, versus -$48.3 million for Q2 2025 and -$62.9 million for Q1 2025.